Context and chronology

French insurtech Alan completed a fresh financing round of €100M, a transaction that revalues the business at €5 billion. The round was led by existing backer Index Ventures and drew new capital from growth investors including Greenoaks and notable business angels. CEO Jean-Charles Samuelian-Werve framed the raise as a bet on product and international scale; on subsequent mention, Mr. Samuelian-Werve signaled prioritized investment in platform capabilities. This funding arrives alongside both private-sector deals and a sizable public-sector engagement announced concurrently.

Performance signals and unit economics

Alan reports a run-rate of €785M ARR, which it says grew roughly 53% year-on-year, and management set a target of $1.16B ARR for 2026. The company also disclosed material improvement in loss dynamics, stating losses have narrowed as a share of revenue, with headline net losses of $61M and $56M in two recent years. In its largest market Alan claims operational profitability at a national level while deliberately trading full-group profitability for accelerated top-line expansion overseas. Investors appear willing to accept that trade-off given the pace of recurring revenue growth and contract wins.

Commercial footprint and market consequence

Commercial traction includes a public-sector contract sized to cover as many as 135,000 civil servants and dependents, and enterprise clients listed in market commentary. Expansion beyond France into Belgium, Spain and Canada accompanies product investment and sales hiring, increasing cross-border regulatory complexity and distribution costs. The new capital reduces short-term cash pressure, enabling sales-led market entry plays that typically favor incumbents with slower product cycles. For venture markets, the raise signals persistent investor appetite for late-stage European insurtech stories even as headline pools of unicorns contract.